Mn Services Vermogensbeheer B.V. Sells 3,500 Shares of Humana Inc. (NYSE:HUM)

Mn Services Vermogensbeheer B.V. reduced its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 7.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 44,512 shares of the insurance provider's stock after selling 3,500 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Humana were worth $11,778,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC grew its position in shares of Humana by 8.0% during the 1st quarter. Exchange Traded Concepts LLC now owns 1,286 shares of the insurance provider's stock worth $340,000 after buying an additional 95 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its stake in Humana by 51.6% in the first quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 438 shares of the insurance provider's stock valued at $116,000 after acquiring an additional 149 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Humana by 144.4% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 15,734 shares of the insurance provider's stock worth $4,163,000 after acquiring an additional 9,296 shares during the period. Pullen Investment Management LLC bought a new stake in shares of Humana during the 1st quarter valued at $403,000. Finally, Fifth Third Bancorp lifted its stake in shares of Humana by 14.4% in the 1st quarter. Fifth Third Bancorp now owns 8,228 shares of the insurance provider's stock valued at $2,177,000 after purchasing an additional 1,034 shares during the period. 92.38% of the stock is owned by institutional investors.

Humana Stock Performance

Humana stock traded up $0.32 during midday trading on Monday, reaching $235.58. 2,305,558 shares of the company's stock were exchanged, compared to its average volume of 1,796,293. The stock's 50-day simple moving average is $250.43 and its 200 day simple moving average is $262.41. The firm has a market cap of $28.43 billion, a price-to-earnings ratio of 23.68, a P/E/G ratio of 2.05 and a beta of 0.43. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 52 week low of $212.45 and a 52 week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. Humana's revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $7.23 EPS. On average, analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.50%. Humana's payout ratio is presently 25.04%.

Wall Street Analyst Weigh In

A number of research firms recently commented on HUM. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. JPMorgan Chase & Co. reduced their target price on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a report on Tuesday, February 18th. Raymond James upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target for the company in a report on Thursday, May 1st. Guggenheim started coverage on Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 price objective on the stock. Finally, Truist Financial lowered their target price on Humana from $325.00 to $305.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Seventeen analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $284.24.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.